Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its upcoming participation at the TD Cowen 45th Annual Health Care Conference.
The company's President and Chief Executive Officer, Sean P. Bohen, M.D., Ph.D., will deliver a presentation on March 5, 2025, at 10:30 a.m. ET.
Investors and interested parties can access a live webcast of the presentation and related materials through the Events and Presentations section of Olema's Investor Relations website at ir.olema.com. A recording will also be made available at the same location following the presentation.
Olema Pharmaceuticals (Nasdaq: OLMA), un'azienda biofarmaceutica in fase clinica specializzata in terapie mirate per il cancro al seno, ha annunciato la sua prossima partecipazione al 45° Congresso Annuale sulla Salute di TD Cowen.
Il Presidente e Amministratore Delegato dell'azienda, Sean P. Bohen, M.D., Ph.D., presenterà il suo intervento il 5 marzo 2025, alle 10:30 a.m. ET.
Investitori e parti interessate possono accedere a un webcast in diretta della presentazione e dei materiali correlati attraverso la sezione Eventi e Presentazioni del sito web delle Relazioni con gli Investitori di Olema all'indirizzo ir.olema.com. Una registrazione sarà inoltre disponibile nello stesso luogo dopo la presentazione.
Olema Pharmaceuticals (Nasdaq: OLMA), una empresa biofarmacéutica en etapa clínica especializada en terapias dirigidas para el cáncer de mama, ha anunciado su próxima participación en la 45ª Conferencia Anual de Salud de TD Cowen.
El Presidente y Director Ejecutivo de la empresa, Sean P. Bohen, M.D., Ph.D., realizará una presentación el 5 de marzo de 2025, a las 10:30 a.m. ET.
Los inversores y partes interesadas pueden acceder a un webcast en vivo de la presentación y los materiales relacionados a través de la sección de Eventos y Presentaciones del sitio web de Relaciones con Inversores de Olema en ir.olema.com. También se hará disponible una grabación en el mismo lugar después de la presentación.
Olema Pharmaceuticals (Nasdaq: OLMA), 유방암을 위한 표적 치료에 전문화된 임상 단계의 생물 의약품 회사가 TD Cowen 제45회 연례 건강 관리 컨퍼런스에 참가할 예정이라고 발표했습니다.
회사의 사장 겸 CEO인 Sean P. Bohen, M.D., Ph.D.가 2025년 3월 5일 오전 10시 30분 ET에 발표를 진행할 예정입니다.
투자자와 관심 있는 사람들은 Olema의 투자자 관계 웹사이트 ir.olema.com의 이벤트 및 발표 섹션을 통해 발표와 관련 자료의 실시간 웹캐스트에 접근할 수 있습니다. 발표 후 같은 위치에서 녹화본도 제공될 예정입니다.
Olema Pharmaceuticals (Nasdaq: OLMA), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies ciblées pour le cancer du sein, a annoncé sa prochaine participation à la 45ème Conférence Annuelle sur la Santé de TD Cowen.
Le Président et Directeur Général de l'entreprise, Sean P. Bohen, M.D., Ph.D., fera une présentation le 5 mars 2025 à 10h30 ET.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation et des documents connexes via la section Événements et Présentations du site des Relations Investisseurs d'Olema à l'adresse ir.olema.com. Un enregistrement sera également disponible au même endroit après la présentation.
Olema Pharmaceuticals (Nasdaq: OLMA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf gezielte Therapien gegen Brustkrebs spezialisiert hat, hat seine bevorstehende Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt.
Der Präsident und CEO des Unternehmens, Sean P. Bohen, M.D., Ph.D., wird am 5. März 2025 um 10:30 Uhr ET eine Präsentation halten.
Investoren und Interessierte können über den Bereich Veranstaltungen und Präsentationen auf der Investor-Relations-Website von Olema unter ir.olema.com auf einen Live-Webcast der Präsentation und der zugehörigen Materialien zugreifen. Eine Aufzeichnung wird nach der Präsentation ebenfalls an derselben Stelle verfügbar sein.
- None.
- None.
SAN FRANCISCO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 10:30 a.m. ET.
A live webcast of the presentation and any accompanying materials will be available under the Events and Presentations section of Olema’s Investor Relations website at ir.olema.com. A recording of the presentation will be made available in the same location.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco, California and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
When is Olema Pharmaceuticals (OLMA) presenting at the TD Cowen Health Care Conference 2025?
How can investors watch Olema Pharmaceuticals' (OLMA) TD Cowen conference presentation?
What is the focus area of Olema Pharmaceuticals (OLMA)?
Who will represent Olema Pharmaceuticals (OLMA) at the 2025 TD Cowen Healthcare Conference?
